McGill.CA / Cancer Prevention / Publications / Dr. Pollak's publications

2004 - 2005

2005

  1. Canil CM, Moore MJ, Winquist E, Baetz T, Pollak M, Chi KN, Berry S, Ernst DS, Douglas L, Brundage M, Fisher B, McKenna A, Seymour L. Randomized Phase II study of two dose of gefitinib in hormone-refractory prostate cancer: a trial of the National Cancer Institute of Canada-Clinical Trial Group. J Clin Oncol 23: 455-60, 2005
  2. Schernhammer ES, Holly JM, Pollak MN, Hankinson SE. Circulating levels of insulin-like growth factors, their binding proteins, and breast cancer risk. Cancer Epidemiol Biomarkers Prev. 3: 699-704, 2005
  3. Kristal AR, King IB, Albanes D, Pollak MN, Stanzyk FZ, Santella RM, Hoque A. Centralized blood precessing for the selenium and vitamin E cancer prevention trial: effects of delayed processing on caroteniods, tocopherols, insulin-like growth factor-I, insulin-like growth factor binding protein 3, steroid hormones, and lymphocyte viability. Cancer Epidemiol Biomarkers Prev. 14: 727-30, 2005
  4. Wei EK, Ma J, Pollak MN, Rifai N, Fuchs CS, Hankinson SE, Giovannucci E. A prospective study of C-peptide, insulin-like growth factor-I, insulin-like growth factor binding protein-1, and the risk of colorectal cancer in women. Cancer Epidemiol Biomarkers Prev.14: 850-5, 2005
  5. Nam RK, Trachtenberg J, Jewitt MA, Toi A, Evans A, Narod SA, Pollak M Serum insulin-like growth factor-1 (IGF-1) levels and prostatic intraepithelial neoplasia: a clue to the relationship between IGF-1 physiology and prostate cancer risk. Cancer Epidemiol Biomarkers Prev.14: 1270-3, 2005
  6. Diorio C, Pollak M, Byrne C, Masse B, Hebert-Croteau N, Yaffe M, Cote G, Berube S, Morin C, Brisson J. Insulin-like growth factor-I, IGF-binding protein-3, and mammographic breast density. Cancer Epidemiol Biomarkers Prev. 14: 1065-73, 2005
  7. Meyerhardt JA, Sloan JA, Sargent DJ, Goldberg RM, Pollak M, Morton RF, Ramanathan RK, Williamson SK, Findlay BP, Fuchs CS. Associations between plasma insulin-like growth factor proteins and c-peptide and quality of life in patients with metastatic colorectal cancer. Cancer Epidemiol Biomarkers Prev. 14: 1402-10, 2005
  8. Platz EA, Pollak MN, Leitzmann MF, Stampfer MJ, Willett WC, Giovannucci E. Plasma insulin-like growth factor-1 and binding protein-3 and subsequent risk of prostate cancer in the PSA era. Cancer Causes and Control. 16: 255-62, 2005
  9. Sutherland BW, Kucab J, Wu J, Lee C, Cheang MC, Yorida E, Turbin D, Dedhar S, Nelson C, Pollak M,Leighton Grimes H, Miller K, Badve S, Huntsman D, Blake-Gilks C, Chen M, Pallen CJ, Dunn SE. Akt phosphorylates the Y-box binding protein 1 at Ser102 located in the cold shock domain and affects the anchorage-independent growth of breast cancer cells. Oncogene 24: 4281-92, 2005
  10. Camirand A, Zakikhani M, Young F, Pollak M Inhibition of insulin-like growth factor-1 receptor signaling enhances growth-inhibitory and proapopotic effects of gefitinib (Iressa) in human breast cancer cells. Breast Cancer Research 7: R570-9, 2005
  11. Majeed N, Blouin MJ, Kaplan-Lefko PJ, Barry-Shaw J, Greenberg NM, Gaudreau P, Bismar TA, Pollak M A germ line mutation that delays prostate cancer progression and prolongs survival in a murine prostate cancer model. Oncogene 24: 4736-40, 2005
  12. Bérubé S, Diorio C, Mâssé B, Hébert-Croteau N, Byrne C, Côté G, Pollak M, Yaffe M, Brisson J. Vitamin D and calcium intakes from food or supplements and mammographic breast density. Cancer Epidemiol Biomarkers Prev. 14: 1553-9, 2005
  13. Pinheiro SP, Holmes MD, Pollak MN, Barieri RL, Hankinson SE. Racial differences in premenopausal endogenous hormones. Cancer Epidemiol Biomarkers Prev. 14: 2147-53, 2005
  14. Kucab JE, Lee C, Chen C, Zhu J, Gilks CB, Cheang M, Huntsman D, Yorida E, Emerman J, Pollak M, Dunn SE. Celecoxib analogues disrupt Akt signaling, which is commonly activated in primary breast tumors. Breast Cancer Res. 7: R796-807, 2005
  15. Levitt R, Georgescu MM, Pollak M, PTEN-induction in U251 glioma cells decreases the expression of insulin-like growth factor binding protein-2. Biochem and Biophys Res Commun 336: 1056-61, 2005
  16. Diorio C, Pollak M, Byrne C, Mâssé B, Hébert-Croteau N, Yaffe M, Côté G, Bérubé S, Brisson J. Levels of C-Peptide and mammographic breast density. Cancer Epidemiol Biomarkers Prev 14: 2661-4, 2005

TOP OF PAGE

Book Chapters, Letters, Serials

  1. Pollak M. Individualizing Interventions for Cancer Prevention. inSenn, H-J, Morant, R.(eds.) Recent Results in Cancer Research 166: 63-70, 2005

TOP OF PAGE

2004

  1. Lu Y, Zi X, Pollak M. Molecular mechanisms underlying IGF-I-induced attenuation of the growth inhibitory activity of trastuzumab (Herceptin) on SKBR3 breast cancer cells. Int J Cancer. 108: 334-41, 2004
  2. Lu Y, Zi X, Zhao Y, Pollak M. Overexpression of ErbB2 receptor inhibits IGF-I-induced Shc-MAPK signaling pathway in breast cancer cells. Biochemical Biophys Res Commun 313: 709-15, 2004
  3. Schairer C, Hill D, Fears T, Ziegler R, Hoover R, Pollak M. Serum concentrations of IGF-I, IGFBP-3, and c-peptide and risk of hyperplasia and cancer of the breast in postmenopausal women. Int J Cancer. 108: 773-9, 2004
  4. Levitt RJ, Buckley J, Blouin MJ, Schaub B, Triche TJ, Pollak M. Growth inhibiton of breast epithelial cells by celecoxib is associated with upregulation of insulin-like growth factor binding protein-3 expression. Biochem Biophys Res Commun. 316: 421-8, 2004
  5. Labrie F, Champagne P, Labrie C, Roy J, Laverdiere J, Provencher L, Potvin M, Drolet Y, Pollak M, Panasci L, L'Esperance B, Dufresne J, Latreille J, Robert J, Samson B, Jolivet J, Yelle L, Cusan L, Diamond P, Candas B. Activity and safety of the antiestrogen EM-800, the orally active precursor of acolbifene, in tamoxifen-resistant breast cancer. J Clin Oncol. 22: 864-71, 2004
  6. Ma J, Giovannucci EL, Pollak MN, Leavitt A, Tao Y, Gaziano J, Stampfer MJ. A prospective study of plasma c-peptide and colorectal cancer risk in men. J Natl Cancer Inst. 96: 546-53, 2004
  7. Lai JH, Vesprini D, Zhang W, Yaffe MJ, Pollak M,, Narod SA. A polymorphic locus in the promoter region of the IGFBP3 gene is related to mammographic breast density. Cancer Epidemiol Biomarkers Prev. 13: 573-82, 2004
  8. Stolzenberg-Solomon RZ, Limburg P, Pollak M, Taylor PR, Virtamo J, Albanes D. Insulin-like growth factor (IGF)-1, IGF-binding protein-3, and pancreatic cancer in male smokers. Cancer Epidemiol Biomarkers Prev. 13: 438-44, 2004
  9. Camirand A, Pollak M. Co-targeting IGF-1R and c-kit: synergistic inhibition of proliferation and induction of apoptosis in H 209 small cell lung cancer cells. Br J Cancer. 90: 1825-9, 2004
  10. Pollak MN, Schernhammer ES, Hankinson SE. Insulin-like growth factors and neoplasia. Solicited Review. Nature Rev Cancer. 4: 505-18, 2004.

TOP OF PAGE

Book Chapters, Letters, Serials

  1. Pollak M. Insulin-like growth factors and neoplasia. Novartis Found Symp. 262:84-98, 98-107, 265-8, 2004.
Back to top